RETINAL THICKNESS CONDITIONS IN THE MACULAR AREA DURING A-VEGF THERAPY ACCORDING TO OCT DIAGNOSTICS

Н.M. Норматова, Ф.Ф. Хамидуллаев

Передовая Офтальмология · 2024-yil

Annotatsiya

Relevance. Macular edema is the leading cause of vision loss in people with diabetes in developed countries, and its prevalence is directly related to the duration of diabetes. Its incidence varies from publication to publication, ranging between 7.5% and 15.2%, and is more common in patients with type 2 diabetes receiving insulin. The significance of the incidence of diabetic macular oedema is directly related to the patient’s metabolic control and the presence of risk factors, as we will see below. The purpose of the study. ОCT of changes of makular network thickness within a-VEGF therapy. Materials and methods. The two study groups comprised 30 patients (30 eyes) aged 52 to 84 years, 15 females and 15 males. The mean age was 65±5 years. Results and conclusions. Retinal thickness in the macula averaged 301.3±19μm versus 238.8±18.0 in Group 1, p<0.05, where macular edema had resolved. When A-VEGF pharmacotherapy is switched to aflibercept in these patients, a pronounced positive dynamic accompanied by a reduction of edema in the macular zone is noted already after loading injections, as confirmed by SOCT and visometry data.

Maqola ma’lumotlari
MualliflarН.M. Норматова, Ф.Ф. Хамидуллаев
JurnalПередовая Офтальмология
Nashr sanasi2024-09-25
Jild9
Son3
Betlar47-51
Tilru
DOI10.57231/j.ao.2024.9.3.010

Передовая Офтальмология jurnalidan boshqa maqolalar

Передовая Офтальмология — barcha maqolalar